• LAST PRICE
    0.1845
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.1845
  • Day Range
    ---
  • 52 Week Range
    Low 0.0323
    High 0.2800
  • Volume
    34
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeNBIO
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNBIO
Nascent Biotech Inc
31.3M
-12.5x
---
United StatesINKT
Mink Therapeutics Inc
31.6M
-1.4x
---
United StatesENZC
Enzolytics Inc
30.0M
-0.1x
---
United StatesPMN
ProMIS Neurosciences Inc
33.0M
-1.0x
---
United StatesLIANY
LianBio
33.1M
-0.4x
---
United StatesBCLI
Brainstorm Cell Therapeutics Inc
29.4M
-1.3x
---
As of 2024-03-28

Company Information

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

Contact Information

Headquarters
631 Us Hwy 1, Suite 407NORTH PALM BEACH, FL, United States 33408
Phone
612-961-5656
Fax
---

Executives

President, Secretary, Director
Sean Carrick
Chief Financial Officer, Chief Accounting Officer, Director
Lowell Holden
Independent Director
Douglas Karas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$31.3M
Revenue (TTM)
$0.00
Shares Outstanding
169.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-3.20
EPS
$-0.01
Book Value
$-0.01
P/E Ratio
-12.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.